Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Eli Lilly & Co. (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. Its products span oncology, diabetes, immunology, neuroscience, and other therapies. The company is one ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The actor said he lost 40 pounds taking GLP-1 medication before a negative side effect necessitated a change to a different ...

She’s racing to a run-through for a 14-course tasting menu she will barely nibble at as she raves about her weight loss on ...

Scientists have developed a single-dose treatment for breast cancer that eliminates small tumors and significantly shrinks larger ones without side effects. Named ErSo-TFPy, this drug shows ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

“We’re saying there are beneficial effects ... liver cancer, kidney disease, bacterial infections, pneumonia and Parkinson’s disease, according to the researchers. On the flip side ...

“It’s hard to make a blanket recommendation, because the side effects are real," study author Dr. Ziyad Al-Aly, chief of research and development at the VA St. Louis Health Care System, told CNN. “I ...

A large study published in Nature Medicine reviewed the effects of GLP-1 drugs like Ozempic and Mounjaro on 175 different ...

More serious side effects like pancreatitis and kidney complications are very rare.” Ozempic, Wegovy, Mounjaro, and Zepbound are all ... stroke, colon cancer, and Alzheimer’s disease.

Formally, these drugs are known as glucagon-like peptide-1 receptor agonists (GLP-1RA) and include Mounjaro and Zepbound ... is sparse on the drugs' effects across the body's organ systems.